Anti–programmed cell death 1 (anti–PD-1) immunotherapy features a durable response and improved survival in a small subset of patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Here, PDCD1 is linked to nasopharyngeal carcinoma.